Correlation Between Inozyme Pharma and Gilead Sciences

Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Gilead Sciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Gilead Sciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inozyme Pharma and Gilead Sciences, you can compare the effects of market volatilities on Inozyme Pharma and Gilead Sciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Gilead Sciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Gilead Sciences.

Diversification Opportunities for Inozyme Pharma and Gilead Sciences

-0.77

Correlation Coefficient

Inozyme Pharma  Gilead Sciences

Pay attention - limited upside

The 3 months correlation between Inozyme and Gilead is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Gilead Sciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Gilead Sciences and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Gilead Sciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gilead Sciences has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Gilead Sciences go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Gilead Sciences

Given the investment horizon of 90 days Inozyme Pharma is expected to generate 3.51 times more return on investment than Gilead Sciences. However, Inozyme Pharma is 3.51 times more volatile than Gilead Sciences. It trades about 0.06 of its potential returns per unit of risk. Gilead Sciences is currently generating about 0.03 per unit of risk. If you would invest  115.00  in Inozyme Pharma on September 14, 2024 and sell it today you would earn a total of  185.00  from holding Inozyme Pharma or generate 160.87% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	99.8%
Values	Daily Returns

Inozyme Pharma  vs.  Gilead Sciences

Inozyme Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Gilead Sciences

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Gilead Sciences are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent essential indicators, Gilead Sciences may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Inozyme Pharma and Gilead Sciences

The main advantage of trading using opposite Inozyme Pharma and Gilead Sciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Gilead Sciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gilead Sciences will offset losses from the drop in Gilead Sciences' long position.

The idea behind Inozyme Pharma and Gilead Sciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.